Hypoxic preconditioning of stem cells and neural progenitor cells has been tested for promoting cell survival after transplantation. The present investigation examined the hypothesis that hypoxic preconditioning of bone marrow mesenchymal stem cells (BMSCs) could not only enhance their survival but also reinforce regenerative properties of these cells. BMSCs from eGFP engineered rats or pre-labeled with BrdU were pretreated with normoxia (20% O 2 , N-BMSCs) or sub-lethal hypoxia (0.5% O 2 . H-BMSCs). The hypoxia exposure up-regulated HIF-1α and trophic/growth factors in BMSCs, including brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), vascular endothelial growth factor (VEGF) and its receptor FIK-1, erythropoietin (EPO) and its receptor EPOR, stromal derived factor-1 (SDF-1) and its CXC chemokine receptor 4 (CXCR4). Meanwhile, many pro-inflammatory cytokines/chemokines were downregulated in H-BMSCs. N-BMSCs or H-BMSCs were intravenously injected into adult rats 24 h after 90-min middle cerebral artery occlusion. Comparing to N-BMSCs, transplantation of H-BMSCs showed greater effect of suppressing microglia activity in the brain. Significantly more NeuN-positive and Glut1-positive cells were seen in the ischemic core and peri-infarct regions of the animals received H-BMSC transplantation than that received N-BMSCs. Some NeuN-positive and Glut-1-positive cells showed eGFP or BrdU immunoflourescent reactivity, suggesting differentiation from exogenous BMSCs into neuronal and vascular endothelial cells. In Rotarod test performed 15 days after stroke, animals received H-BMSCs showed better locomotion recovery compared with stroke control and N-BMSC groups. We suggest that hypoxic preconditioning of transplanted cells is an effective means of promoting their regenerative capability and therapeutic potential for the treatment of ischemic stroke.
Introduction
Stroke is a leading cause of human death and disability in the United States. There are currently very few effective clinical therapies for acute ischemic stroke. Alternatively, cell-based transplantation therapy using embryonic and adult stem cells has provided promising hope to enhance tissue repair and functional recovery after stroke. Among stem cells that are candidates for transplantation in human stroke patients, bone marrow mesenchymal stem cells (BMSCs) are preferred because they are available from autologous donation therefore eliminates ethical disputes and other concerns related to graft rejection (Malgieri et al., 2010) . Basic and clinical studies suggest that human BMSCs are not antigen-presenting cells and would not cause activation of the host's immune system (Tse et al., 2003) , suggesting that even allogeneic BMSCs may be used for transplantation therapies (Li et al., 2006) . In addition, BMSCs have other advantages. For example, BMSCs have an inhibitory action on inflammatory responses, which exacerbates ischemic damage; and they express a variety of neurotrophic and growth factors that may show autocrine and paracrine effects after transplantation (Malgieri et al., 2010; Tse et al., 2003) . Examples of those factors include glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and vascular endothelial growth factor (VEGF); all are important for brain protection and tissue regeneration (Chen et al., 2002; Kurozumi et al., 2005) .
Transplantation of BMSCs promotes the repair and regeneration of nerve tissue within the central and peripheral nervous systems (Nandoe Tewarie et al., 2006) . These cells are being evaluated in human clinical trials for efficacy in treating genetic bone diseases, to speed hematopoietic recovery after bone marrow transplantation and to treat severe graft-versus-host disease (GVHD) (Le Blanc et al., 2008; Singer and Caplan, 2011) . In experimental stroke animal studies, compelling evidence shows that transplantation of BMSCs has promising benefits on functional recovery after ischemic stroke Neurobiology of Disease 46 (2012) [635] [636] [637] [638] [639] [640] [641] [642] [643] [644] [645] 
